Overview

A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
One hundred twenty patients with arterial hypertension and albuminuria (some amount of albumin in urine) are given valsartan 80 mg and then160 mg to normalize blood pressure. Hydrochlorothiazide (diuretic) 12.5-25 mg added if necessary.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Valsartan